{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "2859578",
  "DateCompleted": {
    "Year": "1985",
    "Month": "06",
    "Day": "12"
  },
  "DateRevised": {
    "Year": "2013",
    "Month": "11",
    "Day": "21"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0193-953X",
      "JournalIssue": {
        "Volume": "8",
        "Issue": "1",
        "PubDate": {
          "Year": "1985",
          "Month": "Mar"
        }
      },
      "Title": "The Psychiatric clinics of North America",
      "ISOAbbreviation": "Psychiatr Clin North Am"
    },
    "ArticleTitle": "New findings in anxiety. A synthesis for clinical practice in 1985.",
    "Pagination": {
      "StartPage": "169",
      "EndPage": "175",
      "MedlinePgn": "169-75"
    },
    "Abstract": {
      "AbstractText": [
        "Antidepressant therapy for panic attacks, exposure therapy for stimulus-dependent anxieties, and, to a lesser extent, clomipramine therapy for obsessive-compulsive symptoms have transformed the treatment of anxiety disorders and ushered in an era of rapid progress in research on anxiety and anxiety disorders. In most cases, these symptomatic treatments should be recommended first. After these approaches have produced maximal benefit, other treatments can be considered if indicated."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Curtis",
        "ForeName": "G C",
        "Initials": "GC"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Psychiatr Clin North Am",
    "NlmUniqueID": "7708110",
    "ISSNLinking": "0193-953X"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anti-Anxiety Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antidepressive Agents, Tricyclic"
    },
    {
      "RegistryNumber": "12794-10-4",
      "NameOfSubstance": "Benzodiazepines"
    },
    {
      "RegistryNumber": "NUV44L116D",
      "NameOfSubstance": "Clomipramine"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Anti-Anxiety Agents"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Antidepressive Agents, Tricyclic"
    },
    {
      "QualifierName": [
        "diagnosis",
        "psychology",
        "therapy"
      ],
      "DescriptorName": "Anxiety"
    },
    {
      "QualifierName": [
        "diagnosis",
        "psychology",
        "therapy"
      ],
      "DescriptorName": "Anxiety Disorders"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Behavior Therapy"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Benzodiazepines"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Clomipramine"
    },
    {
      "QualifierName": [
        "diagnosis",
        "psychology",
        "therapy"
      ],
      "DescriptorName": "Depressive Disorder"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Diagnosis, Differential"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Psychotherapy"
    }
  ]
}